Mesoporous Silica Hybridized With Gadolinium(III) Nanoplatform for Targeted Magnetic Imaging–Guided Photothermal Breast Cancer Therapy

Abstract

Achieving drug target accumulation in antitumor tissue, simultaneous diagnostic imaging, and optimal release behavior with treatment needs a best chemotherapy procedure involving receptive switch of drug delivery. Constructed on mesoporous silica nanoparticles, which are crossed with multiscale charming nanoparticles for magnetic resonance imaging (MRI)-aided and alternate magnetic field (AMF) response chemotherapy for breast cancer, we report in this work the assembly of a new theranostics drug conveyance process. Hydrothermal processes (gadolinium(III) oxide nanoparticles [Gd-NPs]) and heat decomposition process (radical size uFe-NPs) were used to prepare superparamagnetic Gd-NPs with multiscale sizes. Gadolinium(III) oxide nanoparticles act as an AMF-responsive heat mediator, while ultra-Fe nanoparticles (uFe-NPs) act as an MRI T2 contrast mediator. Nanoparticles of the mesoporous silica with radially oriented mesochannels were further grown in situ on the surfaces of the Gd-NPs, and the uFe-NPs anticancer drug doxorubicin can be easily incorporated in the mesochannels. To provide better targeting capabilities for the as-synthesized biotin-loaded nanohybrids, the particle surfaces are updated with biotin (Bt). This optimized drug conveyance method based on nanocomposites of SiO2 demonstrated great efficiency of medication charging and receptive properties of AMF stimulus release. However, tests of MRI in vitro showed an outstanding contrast effect in MRI with a high stimulation quality (299 mM−1 s−1). In contrast, the study of in vitro cytotoxicity assessment revealed that an MRI-directed stimulus-mediated theranostics tool can be used as a drug conveyance device to efficiently treat breast cancer.

Gadolinium-Coated Mesoporous Silica Nanoparticle for Magnetic Resonance Imaging

“…As-prepared contrast materials were injected into healthy SD rats for in-vivo imaging to evaluate Gd 2 O 3 @MSN as an in-vivo MRI contrast agent. Previous studies have shown that MSN adsorbs plasma proteins and interacts strongly with the tissue-resident macrophages in the mononuclear phagocyte system (MPS), leading to rapid blood clearance and accumulation in the liver and spleen ( Gao et al, 2011 ; Ekkapongpisit et al, 2012 ; Li et al, 2016 ; Wang and Sun, 2020 ). Given this, we used the likely accumulation of our NPs in the hepatic Kupffer cells to determine our ROIs, focusing on the liver region.…”

“…These NDDS combine a therapeutic payload with nano-sized carriers (such as liposomes, gold nanoparticles, polymeric micelles, and mesoporous silica) to reduce side effects and prolong circulation time ( Mikada et al, 2017 ; Layek et al, 2020 ). Thus, the introduction of MRI contrast agents into an NDDS may both extend blood circulation time and improve MRI performance (because of the shortened longitudinal proton relaxation time of the surrounding water molecules for T 1 -type contrast agents) ( Lin et al, 2004 ; Parvesh et al, 2012 ; Li et al, 2014 ; Hu et al, 2015 ; Deng et al, 2016 ; Wang and Sun, 2020 ). Of the common NDDS carriers mesoporous silica nanoparticles (MSNs) are widely used in the carriers for drug delivery and biosensing and are likely to be the most appropriate carrier for gadolinium owing to their high surface area, ease of preparation, good biocompatibility, and mesoporous structure ( Lin et al, 2004 ; Taylor et al, 2008 ; Xia et al, 2019 ).…”

An EGF-modified PLGA-lanthanide nanoplatform for combined NIR-II cancer imaging and targeted drug delivery

“…To examine the effect of photothermal conversion of CaF 2 :Y,Nd NPs under laser irradiation, real-time thermograms and temperature changes after irradiation were recorded using an infrared thermographer (Fluke Ti32, Fluke Corporation, USA) [33][34][35][36]. Specifically, 100 μg/mL of CaF 2 :Y,Nd NPs and saline (control) were stored in a 12-well plate.…”